Deals In Depth: December 2016
Executive Summary
Incyte and Merus signed a broad bispecific antibody collaboration worth $3 million. Lonza acquired contract development and manufacturing organization Capsugel for $5.5 billion. Biopharma companies raised $2.5 billion in December, while funding for device firms was down to just $103 million.
You may also be interested in...
Deals In Depth: November 2019
Allergan signed an $800m deal to investigate Exicure's Spherical Nucleic Acid (SNA) gene regulation and immune modulation technology for the treatment of hair loss. Novartis invested in cardiology through the $9.7bn acquisition of The Medicines Co. Biopharma financing greatly increased due to the $30bn notes offering done by AbbVie to fund part of the Allergan deal.
Device/Diagnostics Quarterly Dealmaking Statistics, Q3 2019
Device financing increased substantially in Q3, thanks to debt raises led by Insulet. Acquisition dollar volume dropped, though, but Siemens' buy of Corindus for $1.1bn was a stand-out. Diagnostics/research tools financing dropped by 28% from Q2, while acquisition value greatly increased due to Exact Sciences' $2.8bn purchase of Genomic Health.
Deals In Depth: October 2019
BeiGene gained rights to three Amgen drugs in China in a deal worth $1.25bn, while Amgen took a $2.7bn stake in BeiGene. Nestle Skin Health was spun out as Galderma and sold to private equity for $10bn. Biopharma financing maintained the levels seen in previous months, but device funding was down.
Need a specific report? 1000+ reports available
Buy Reports